It was found that the PS modified ODN1411 could competitively inhibit the signal transduction of TLR8 by interacting with TLR8, that is, it inhibited the production of inflammatory factors in RA model by inhibiting the phosphorylation of signal molecules and the activation of NF-κB, which provided a possible new therapy for the treatment of RA (Sacre et al., 2016). The gene discussed is NFKB1; the disease is rheumatoid arthritis.